Cardioxane® is a cardioprotective treatment option which is indicated in adults for the prevention of chronic cumulative cardiotoxicity caused by anthracycline use in advanced and/or metastatic breast cancer patients who have received a prior cumulative dose of 300mg/m2 of doxorubicin or a prior cumulative dose of 540mg/m2 of epirubicin when further anthracycline treatment is required.
0 σχόλια:
Δημοσίευση σχολίου